Medtronic Raises 2027 Forecasts Amid Heart Device Surge
Medtronic increases 2027 revenue forecasts, driven by strong demand for cardiovascular devices and strategic investments.
Medtronic has revised its financial projections for fiscal 2027, citing robust demand for its cardiovascular devices. The company announced an increase in its expected revenue growth rate, now forecasted to be between 7.25% and 7.75%, up from the previously projected 6.75% to 7.25%. This optimism is bolstered by the performance of its heart devices, which are widely used in complex cardiovascular procedures.
Strategic Investments to Drive Growth
In a move to further capitalize on its growth trajectory, Medtronic has committed to significant investments in related technologies. The company plans to invest $80 million in Pi-Cardia, a maker of heart-valve repair devices, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in selected international markets. CEO Geoff Martha highlighted the importance of these investments, emphasizing their potential to tap into large, high-growth segments within the medtech industry.
Financial Performance and Market Impact
Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by its pulsed field ablation portfolio, which saw an impressive 88% surge. The company reported an adjusted quarterly profit of $1.45 per share on $9.76 billion in revenue, surpassing analyst expectations of $1.39 per share on $9.55 billion in sales, according to LSEG data.
Chief Financial Officer Thierry Pieton noted that the company received tariff refunds that nearly offset the duties paid during the quarter. However, these refunds have not been factored into future financial outlooks.
Future Prospects in Emerging Markets
Martha expressed confidence in the company's strategic direction, particularly in the realm of robotic surgery. With the penetration of soft tissue robotic surgery in emerging markets remaining below 1%, the acquisition of Cornerstone's Sentire device is seen as complementary to Medtronic's existing Hugo device, potentially expanding its market share in these regions.
Overall, Medtronic's focus on innovation and strategic investments appears to be paying off, positioning the company to meet its enhanced financial targets while addressing the growing global demand for advanced cardiovascular solutions.